Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual ConferencePRNewsWire • 09/13/21
Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease TreatmentBenzinga • 06/29/21
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye DiseasePRNewsWire • 06/29/21
Palatin Technologies' (PTN) CEO Carl Spana on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/17/21
Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate UpdatePRNewsWire • 05/17/21
Palatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in Inflammation and the Treatment of Ocular IndicationsPRNewsWire • 05/14/21
Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021PRNewsWire • 05/13/21
Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)PRNewsWire • 05/04/21
Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingPRNewsWire • 04/20/21
Palatin Technologies to Participate in H.C. Wainwright Global Life Sciences Virtual ConferencePRNewsWire • 03/05/21
Palatin Technologies' (PTN) CEO Carl Spana on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/17/21
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 02/17/21
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business HighlightsPRNewsWire • 02/17/21
Palatin Technologies, Inc. to Report Second Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on February 17, 2021PRNewsWire • 02/12/21
Palatin Shares Spikes On International Patent Application Covering Its Dry Eye Disease CandidateBenzinga • 02/10/21
Palatin Technologies Announces Filing of International Patent Application Claiming PL9643PRNewsWire • 02/10/21
Has Palatin Technologies (PTN) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/04/21